Department of Otolaryngology-Head and Neck Surgery, VU University Medical Center, Cancer Center Amsterdam, The Netherlands.
Department of Epidemiology and Biostatistics, VU University Medical Center, Cancer Center Amsterdam, The Netherlands.
Int J Cancer. 2018 Jul 15;143(2):283-288. doi: 10.1002/ijc.31315. Epub 2018 Mar 2.
Human papillomavirus (HPV)-induced oropharyngeal squamous cell carcinoma (OPSCC) remains increasing worldwide. We aimed to investigate if the HPV-prevalence of OPSCC in the Netherlands is rising as well, also in female patients. In addition, we evaluated the association between HPV-positive OPSCC and suspicious Pap results of the cervix in these female patients. Patients with OPSCC treated in the period 2000-2015 at the VU University Medical Center Amsterdam, were included (n = 926). The presence of an oncogenic HPV infection was determined by p16-immunostaining, followed by a high-risk HPV general primer 5+/6+ DNA PCR on the p16-immunopositive cases. A review of pathology reports in all female patients (n = 305) was undertaken to identify cytological signs of HPV-related (pre)cancer of the cervix. In total 281 of 926 (30.3%) OPSCCs were HPV-positive. Moreover, a significant increase in the prevalence of HPV-positive OPSCCs was observed from 14.0% in 2000 to 48.1% in 2015 (p < 0.001). Among the female patients with an HPV-positive OPSSC (n = 70), the results of cervical smears were available in 56 of 70 patients (80.0%). Of the female patients with HPV-positive OPSCC, 9 of 56 (16.1%) patients had a vaginal cuff Papanicolaou (Pap) test ≥3b in their medical history compared to 7 of 168 (4.2%) in the HPV-negative group (p = 0.003). In conclusion, a continuous increase in the HPV-attributable fraction of OPSCC was demonstrated in the period 2000-2015 in the Amsterdam region. HPV-positive OPSCC has a significant association with a history of suspicious Pap results of the cervix in female patients.
人乳头瘤病毒（HPV）引起的口咽鳞状细胞癌（OPSCC）在全球范围内仍呈上升趋势。我们旨在研究荷兰的 OPSCC 中 HPV 阳性率是否也在上升，包括女性患者。此外，我们评估了 HPV 阳性 OPSCC 与这些女性患者宫颈可疑巴氏涂片结果之间的相关性。纳入 2000 年至 2015 年期间在阿姆斯特丹 VU 大学医学中心治疗的 OPSCC 患者（n=926）。通过 p16 免疫组化检测确定是否存在致癌 HPV 感染，然后对 p16 免疫阳性病例进行高危型 HPV 通用引物 5+/6+DNA PCR。对所有女性患者（n=305）的病理报告进行了回顾，以确定与 HPV 相关的（前）宫颈癌的细胞学征象。在 926 例 OPSCC 中，共有 281 例（30.3%）为 HPV 阳性。此外，从 2000 年的 14.0%到 2015 年的 48.1%，观察到 HPV 阳性 OPSCC 的患病率显著增加（p<0.001）。在 HPV 阳性 OPSCC 女性患者（n=70）中，70 例中有 56 例（80.0%）的宫颈涂片结果可用。在 HPV 阳性 OPSCC 女性患者中，9 例（16.1%）有阴道残端巴氏涂片（Pap）检测≥3b，而 HPV 阴性组有 7 例（4.2%）（p=0.003）。总之，在 2000 年至 2015 年期间，在阿姆斯特丹地区证明 OPSCC 中 HPV 相关比例持续增加。HPV 阳性 OPSCC 与女性患者宫颈可疑巴氏涂片结果史显著相关。
